Impax Laboratories appoints Richard A. Bierly to board
Mr. Bierly was most recently the Chief Financial Officer of Medivation. Prior to joining Medivation, he served as an Executive Director in Ernst & Young LLP's Financial Accounting Advisory Services practice for life sciences and other clients.
Mr. Bierly spent more than a dozen years serving in several leadership roles at Johnson & Johnson (JNJ), including as Vice President, Global Finance Services.
During his tenure at JNJ, Mr. Bierly also served as Vice President, Finance of Centocor and as Vice President, Finance, of Ortho Biotech LP, both subsidiaries of JNJ.
Before joining JNJ, he held various staff and leadership positions in finance and accounting at Aventis, SmithKline and Ernst & Young LLP.
Mr. Bierly currently serves as a director on the Board of Directors and as Chairman of the Audit Committee of Aclaris Therapeutics, Inc., a Nasdaq listed clinical stage pharmaceutical company.
Mr. Bierly received his B.A. degree from Pennsylvania State University and is a Certified Public Accountant in Pennsylvania (inactive) and New Jersey (inactive). ■
LATEST MOVES FROM California
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
- Lombard Medical appoints Kurt Lemvigh as CEO
More inside POST